Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6867461 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: RO6867461 | EXPERIMENTAL | Single doses |
| Part B: RO6867461 | EXPERIMENTAL | Multiple doses |
| Name | Type | Description |
|---|---|---|
| RO6867461 | DRUG | Single or multiple ascending dose by intravitreal injection |
Inclusion Criteria: * Adult patients, \>/= 50 years of age * Patients with age-related macular degeneration (AMD) * Best corrected visual acuity (BCVA) of 20/40 to 20/400 (Snellen equivalent, on ETDRA charts) inclusive * Evidence of leakage due to choroidal neovascularization (CNV) Exclusion Crite...
RO6867461 is an investigational small molecule being studied for the treatment of macular degeneration, specifically wet age-related macular degeneration. It is administered in single and multiple ascending doses to patients with this condition. The drug is currently in Phase 1 clinical development.
RO6867461 is being developed by Roche Holding AG, a company traded under the ticker RHHBY. Roche is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in patients with wet age-related macular degeneration.
RO6867461 is in Phase 1 clinical development. A Phase 1 study has been completed, which evaluated the drug in single and multiple ascending doses in patients with wet age-related macular degeneration. The drug is investigational and not yet approved for any use.
RO6867461 has one completed clinical trial, identified as NCT01941082. This Phase 1 study evaluated single and multiple ascending doses of the drug in patients with wet age-related macular degeneration. The trial enrolled 24 participants and was conducted in the United States and United Kingdom.
RO6867461 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for wet age-related macular degeneration. A Phase 1 trial has been completed, but the drug has not yet received regulatory approval for any indication.